AmerisourceBergen Launches Cell and Gene Therapy Innovation Hub
AmerisourceBergen, a global healthcare company, has announced the launch of its Cell and Gene Therapy (CGT) Integration Hub, a system that can be integrated with biopharma or provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the treatment development and patient journey.
The CGT Integration Hub – which is platform-agnostic and powered by AmerisourceBergen’s innovative customer relationship management (CRM) system – aims to streamline the path-to-care process, in part, by providing physicians and patient services teams with enhanced visibility across the therapy development and delivery process.
“Cell and gene therapies offer tremendous promise but the unique characteristics of these treatments – coupled with the urgency with which they need to be delivered – requires flawless execution and heightened coordination from the moment a patient is identified all the way through the treatment administration,” said Dale Hanna, Director of Cell & Gene Therapy Solutions at AmerisourceBergen. “Through the CGT Integration Hub, our goal is to increase connectivity and reduce potential barriers across the patient journey, simplifying the care coordination process and enabling an enhanced patient and provider experience.”
AmerisourceBergen offers CGT developers support at each stage of the product lifecycle, including third-party logistics services, regulatory consulting, market access and reimbursement support, clinical trial and commercial distribution and patient support services. With the CGT Integration Hub, AmerisourceBergen can complete platform integrations with various supply chain partners, including therapy developers and CGT software providers. For example, AmerisourceBergen recently completed a platform integration with TrakCel’s cell orchestration platform OCELLOS.
“We are on the verge of several landmark CGT approvals this year in the United States, which reflects the rapid pace at which this sector is moving. But the healthcare system needs to keep pace with the science,” said Lung-I Cheng, Vice President of Cell & Gene Therapy at AmerisourceBergen. “Our role in the pharmaceutical supply chain, coupled with our commercialization expertise, enables us to play a vital role in helping to advance innovation and access to these products. We continue to focus on how we can create a more connected CGT ecosystem and introduce novel solutions that meet the needs of our biopharma partners, healthcare providers and patients.”
- Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development Read more
- Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer Read more
- Feinstein Institutes Bioelectronic Medicine Researchers Stimulate Vagus Nerve to Reduce Bleeding in Hemophilia Read more
- Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis Read more
- Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency Read more